Silence Therapeutics PLC Silence Therapeutics Presents New Data (9758D)

TIDMSLN

RNS Number : 9758D

Silence Therapeutics PLC

03 May 2017

Silence presents new data

3 May 2017

Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that it has presented new pre-clinical data generated using its GalNAc-siRNA platform technology, including the translation of effective liver target knockdown into higher species, at the TIDES: Oligonucleotides and Peptide Therapeutics meeting in San Diego. The presentation is available on the Company's website, www.silence-therapeutics.com.

Enquiries:

 
 Silence Therapeutics plc                  Tel: +44 (0)20 
  Ali Mortazavi, Chief Executive Officer    3457 6900 
  David Ellam, Chief Financial Officer 
 Canaccord Genuity Limited (Nominated      Tel: +44 (0)20 
  Adviser and Joint Broker)                 7523 8350 
  Henry Fitzgerald-O'Connor/Emma Gabriel 
 Peel Hunt LLP (Joint Broker)              Tel: +44 (0)20 
  James Steel/Oliver Jackson                7418 8900 
 Media Enquiries:                          Tel: +44 (0) 
  FTI Consulting                            20 3727 1000 
  Simon Conway/Brett Pollard/Stephanie 
  Cuthbert 
 

Notes to Editors

About Silence Therapeutics plc

Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCUGUQCAUPMPUP

(END) Dow Jones Newswires

May 03, 2017 02:01 ET (06:01 GMT)